Literature DB >> 19411469

The effect of platelet-rich plasma and bone marrow on murine posterolateral lumbar spine arthrodesis with bone morphogenetic protein.

Raj D Rao1, Krishnaj Gourab, Vaibhav B Bagaria, Vinod B Shidham, Umesh Metkar, Brian C Cooley.   

Abstract

BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has had limited success in stimulating osteogenesis at the site of posterolateral lumbar spine arthrodesis when used at the currently approved human dose for anterior lumbar interbody arthrodesis. The objective of the present study was to investigate the effect of co-administration of fresh harvested autologous bone marrow aspirate and platelet-rich plasma on rhBMP-2-mediated in vivo murine posterolateral lumbar spine arthrodesis.
METHODS: Forty adult male mice underwent posterolateral intertransverse process arthrodesis from L4 to L6. In three experimental groups, a collagen sponge was placed on each side, overlaying the decorticated transverse processes. Each collagen sponge was presoaked for fifteen minutes with 31 microg of rhBMP-2 in a 100-microL solution containing either saline solution (n = 10), platelet-rich plasma (n = 10), or donor bone-marrow cells (n = 10). Control mice underwent decortication alone (n = 10). The lumbar spine was harvested four weeks after surgery, and spinal fusion was evaluated on the basis of radiographs, computed tomography, and histological analysis.
RESULTS: Control mice showed no evidence of spinal fusion. The rate of fusion was radiographically and histologically similar in all three experimental groups. The area, volume, and density of the fusion mass were significantly greater (p < 0.05) for the group treated with rhBMP-2 and bone marrow as compared with the group treated with rhBMP-2 alone. The group treated with rhBMP-2 and platelet-rich plasma had intermediate fusion area and density. Histologically, the spines treated with rhBMP-2 alone consistently showed the presence of cortical bone between the two transverse processes but fewer trabeculae within the fusion mass; bone marrow co-augmentation resulted in more trabeculae within the fusion mass and a thicker cortical perimeter.
CONCLUSIONS: The present study quantitatively confirmed a synergistic effect of bone marrow cells when added to rhBMP-2 in an in vivo mouse posterolateral lumbar spine fusion model. The volume, area, and density of the fusion mass were significantly increased by augmentation with bone marrow cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411469     DOI: 10.2106/JBJS.G.01375

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

1.  An immunohistochemical analysis of a rat model of proliferative vitreoretinopathy and a comparison of the expression of TGF-β and PDGF among the induction methods.

Authors:  Xiao-Zhi Zheng; Lian-Fang Du; Hui-Ping Wang
Journal:  Bosn J Basic Med Sci       Date:  2010-08       Impact factor: 3.363

2.  Evaluation of autologous platelet concentrate for intertransverse lumbar fusion.

Authors:  Gonzalo Acebal-Cortina; Miguel A Suárez-Suárez; Constantino García-Menéndez; Luis Moro-Barrero; Roberto Iglesias-Colao; Ana Torres-Pérez
Journal:  Eur Spine J       Date:  2011-07-23       Impact factor: 3.134

Review 3.  Spinal fusion in the next generation: gene and cell therapy approaches.

Authors:  Marta Barba; Claudia Cicione; Camilla Bernardini; Vincenzo Campana; Ernesto Pagano; Fabrizio Michetti; Giandomenico Logroscino; Wanda Lattanzi
Journal:  ScientificWorldJournal       Date:  2014-01-28

Review 4.  Mesenchymal Stem Cells for the Treatment of Spinal Arthrodesis: From Preclinical Research to Clinical Scenario.

Authors:  F Salamanna; M Sartori; G Barbanti Brodano; C Griffoni; L Martini; S Boriani; M Fini
Journal:  Stem Cells Int       Date:  2017-02-13       Impact factor: 5.443

Review 5.  Platelet-rich plasma in bone regeneration: engineering the delivery for improved clinical efficacy.

Authors:  Isaac A Rodriguez; Emily A Growney Kalaf; Gary L Bowlin; Scott A Sell
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.